James B Dale

Summary

Country: USA

Publications

  1. ncbi Anti-phagocytic mechanisms of Streptococcus pyogenes: binding of fibrinogen to M-related protein
    Harry S Courtney
    Veterans Affairs Medical Center, University of Tennessee Health Science Center, Memphis, TN 38104, USA
    Mol Microbiol 59:936-47. 2006
  2. ncbi Current status of group A streptococcal vaccine development
    James B Dale
    University of Tennessee Health Science Center, Memphis 38104, USA
    Adv Exp Med Biol 609:53-63. 2008
  3. ncbi Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections
    Mary A Hall
    Department of Veterans Affairs Medical Center, University of Tennessee Health Science Center, Memphis, Tennessee 38104, USA
    Infect Immun 72:2507-12. 2004
  4. ncbi The NH(2)-terminal region of Streptococcus pyogenes M5 protein confers protection against degradation by proteases and enhances mucosal colonization of mice
    Thomas A Penfound
    Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA
    J Infect Dis 201:1580-8. 2010
  5. ncbi Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes
    James B Dale
    Department of Veterans Affairs, The University of Health Science Center, Memphis, TN 38104, USA
    Clin Diagn Lab Immunol 12:833-6. 2005
  6. ncbi Southern Society for Clinical Investigation Founders' Medal recipient's address
    James B Dale
    University of Tennessee College of Medicine, Memphis, USA
    Am J Med Sci 324:61-6. 2002
  7. ncbi Antibodies against a synthetic peptide of SagA neutralize the cytolytic activity of streptolysin S from group A streptococci
    James B Dale
    Department of Veterans Affairs Medical Center and Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38104, USA
    Infect Immun 70:2166-70. 2002
  8. ncbi Potential coverage of a multivalent M protein-based group A streptococcal vaccine
    James B Dale
    University of Tennessee Health Science Center, Department of Medicine and Veterans Affairs Medical Center Research Service, Memphis, TN, USA
    Vaccine 31:1576-81. 2013
  9. ncbi Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci
    Harry S Courtney
    Veterans Affairs Medical Center and Department of Medicine, University of Tennessee, Memphis, Tennessee 38104, USA
    Infect Immun 71:5097-103. 2003
  10. ncbi Immunogenicity of a 26-valent group A streptococcal vaccine
    Mary C Hu
    ID Biomedical Corporation, Bothell, Washington, USA
    Infect Immun 70:2171-7. 2002

Collaborators

Detail Information

Publications21

  1. ncbi Anti-phagocytic mechanisms of Streptococcus pyogenes: binding of fibrinogen to M-related protein
    Harry S Courtney
    Veterans Affairs Medical Center, University of Tennessee Health Science Center, Memphis, TN 38104, USA
    Mol Microbiol 59:936-47. 2006
    ..This may be a common mechanism for evasion of phagocytosis because Mrp is expressed by approximately half of the clinical isolates of S. pyogenes...
  2. ncbi Current status of group A streptococcal vaccine development
    James B Dale
    University of Tennessee Health Science Center, Memphis 38104, USA
    Adv Exp Med Biol 609:53-63. 2008
    ..Successful deployment of safe and effective vaccines to prevent GAS infections and their complications could potentially have a significant impact on the health of millions of people around the world...
  3. ncbi Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections
    Mary A Hall
    Department of Veterans Affairs Medical Center, University of Tennessee Health Science Center, Memphis, Tennessee 38104, USA
    Infect Immun 72:2507-12. 2004
    ..Our results indicate that intranasal delivery of adjuvanted multivalent M protein vaccines induces protective antibody responses and may provide an alternative to parenteral vaccine formulations...
  4. ncbi The NH(2)-terminal region of Streptococcus pyogenes M5 protein confers protection against degradation by proteases and enhances mucosal colonization of mice
    Thomas A Penfound
    Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA
    J Infect Dis 201:1580-8. 2010
    ..The NH(2)-terminal sequence of the M protein from group A streptococci defines the serotype of the organism and contains epitopes that evoke bactericidal antibodies...
  5. ncbi Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes
    James B Dale
    Department of Veterans Affairs, The University of Health Science Center, Memphis, TN 38104, USA
    Clin Diagn Lab Immunol 12:833-6. 2005
    ....
  6. ncbi Southern Society for Clinical Investigation Founders' Medal recipient's address
    James B Dale
    University of Tennessee College of Medicine, Memphis, USA
    Am J Med Sci 324:61-6. 2002
  7. ncbi Antibodies against a synthetic peptide of SagA neutralize the cytolytic activity of streptolysin S from group A streptococci
    James B Dale
    Department of Veterans Affairs Medical Center and Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38104, USA
    Infect Immun 70:2166-70. 2002
    ..Our data also provide convincing evidence that the sagA gene actually encodes the SLS peptide of GAS. The synthetic peptide may prove to be an important component of vaccines designed to prevent GAS infections...
  8. ncbi Potential coverage of a multivalent M protein-based group A streptococcal vaccine
    James B Dale
    University of Tennessee Health Science Center, Department of Medicine and Veterans Affairs Medical Center Research Service, Memphis, TN, USA
    Vaccine 31:1576-81. 2013
    ..The current study evaluated the potential coverage of a new 30-valent M protein-based vaccine using GAS isolates from school children in Bamako, Mali, a population at high risk for the development of RHD...
  9. ncbi Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci
    Harry S Courtney
    Veterans Affairs Medical Center and Department of Medicine, University of Tennessee, Memphis, Tennessee 38104, USA
    Infect Immun 71:5097-103. 2003
    ....
  10. ncbi Immunogenicity of a 26-valent group A streptococcal vaccine
    Mary C Hu
    ID Biomedical Corporation, Bothell, Washington, USA
    Infect Immun 70:2171-7. 2002
    ..Our results indicate that type-specific, protective M protein epitopes can be incorporated into complex, multivalent vaccines designed to elicit broadly protective opsonic antibodies in the absence of tissue-cross-reactive antibodies...
  11. ncbi Dynamic epidemiology of group A streptococcal serotypes
    James B Dale
    Lancet 359:889. 2002
  12. ncbi Temporal changes in streptococcal M protein types and the near-disappearance of acute rheumatic fever in the United States
    Stanford T Shulman
    Division of Infectious Diseases, Children s Memorial Hospital, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
    Clin Infect Dis 42:441-7. 2006
    ..It has been proposed that certain M types of group A streptococci (GAS) include strains that are particularly rheumatogenic and that others are nonrheumatogenic...
  13. ncbi Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles--report of a National Institute of Allergy and Infectious Diseases workshop
    Alan L Bisno
    University of Miami Miller School of Medicine, Miami, Florida 33125, USA
    Clin Infect Dis 41:1150-6. 2005
    ..This report summarizes the deliberations of the workshop...
  14. ncbi Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers
    Shelly A McNeil
    Clinical Trials Research Center, IWK Health Centre, Dalhousie University, Halifax, Nova Scotia, Canada
    Clin Infect Dis 41:1114-22. 2005
    ..New molecular techniques have allowed the previous obstacles to be largely overcome...
  15. ncbi Molecular mechanisms of adhesion, colonization, and invasion of group A streptococci
    Harry S Courtney
    Veterans Affairs Medical Center, Department of Medicine, Memphis, TN, USA
    Ann Med 34:77-87. 2002
    ..In this review, we present the different molecular mechanisms of adhesion utilized by group A streptococci and how these interactions lead to colonization and invasion...
  16. ncbi Group A streptococcal pharyngitis serotype surveillance in North America, 2000-2002
    Stanford T Shulman
    Division of Infectious Diseases, Children s Memorial Hospital, Chicago, IL, USA
    Clin Infect Dis 39:325-32. 2004
    ....
  17. ncbi Presentation of the Southern Society for Clinical Investigation 2002 Founders' Medal to Dr. James B. Dale
    Andrew H Kang
    Department of Medicine, University of Tennessee College of Medicine, Memphis 39163, USA
    Am J Med Sci 324:57-60. 2002
  18. ncbi Progress in group A streptococcal vaccine development
    Karen L Kotloff
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA
    Pediatr Infect Dis J 23:765-6. 2004
  19. ncbi Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial
    Karen L Kotloff
    Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA
    JAMA 292:709-15. 2004
    ..Group A streptococcal infections and their sequelae represent a global health problem. Recent advances have allowed previous obstacles associated with group A streptococcal vaccine development to be overcome...
  20. ncbi Mapping the fibrinogen-binding domain of serum opacity factor of group a streptococci
    Harry S Courtney
    Department of Medicine, University of Tennessee, Memphis, TN, USA
    Curr Microbiol 44:236-40. 2002
    ..These data suggest that fibrinogen and fibronectin bind to the same domain within SOF. It remains to be determined whether the binding of fibrinogen to SOF contributes to the virulence of group A streptococci...
  21. ncbi The importance of the group a streptococcus capsule in the pathogenesis of human infections: a historical perspective
    Gene H Stollerman
    Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
    Clin Infect Dis 46:1038-45. 2008
    ..We believe that it is time to refocus newer clinical studies and techniques on achieving early recognition of potentially dangerous, heavily encapsulated strains of GAS for which spread may be prevented...